(1 - 7 von 11
)
Octapharma stellt ein Update zur Entwicklung von …
www.finanznachrichten.de
Guido Kohla (Octapharma Research Development, Berlin) erläuterte das Grundprinzip für die Entwicklung von SubQ-8 und die Herausforderung bei der Erzielung einer ausreichenden FVIII-Bioverfügbarkeit...
Octapharma communicates an update on the development of SubQ-8, a...
www.octapharmausa.com
Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019
Octapharma stellt ein Update zur Entwicklung von SubQ boerse.de
www.boerse.de
Schließlich ging Sidonio auf die Herausforderungen der intravenösen Gabe des Arzneimittels ein. Guido Kohla (Octapharma Research & Development, Berlin) ...
Octapharma communicates an update on the Financial Post
financialpost.com
— Guido Kohla (Octapharma Research & Development, Berlin, Germany) explained the rationale for the development of SubQ-8 and the challenge of ... › pmn › o...
Octapharma communicates an update on the development ...Financial Post
financialpost.com
— Guido Kohla (Octapharma Research & Development, Berlin, Germany) explained the rationale for the development of SubQ-8 and the challenge of ...
Octapharma communicates an update on the development of ...octapharma.at
www.octapharma.at
— Guido Kohla (Octapharma Research & Development, Berlin, Germany) explained the rationale for the development of SubQ-8 and the challenge of ...
옥타파마, SubQ-8 개발 최신 정보 제공 ...kmdianews.com
www.kmdianews.com
— 귀도 콜라(Guido Kohla, 옥타파마 R&D, 베를린/독일)는 SubQ-8 개발의 이론적 근거와 피하 투여 후 FVIII가 충분한 생체흡수율을 달성하는 과제에 ...
sortiert nach Relevanz / Datum